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Background: Recent advances in bronchoscopy, such as transbronchial biopsy (TBB) using endobronchial
ultrasonography with a guide sheath (EBUS-GS), have improved the diagnostic yield of small-sized peripheral lung
lesions. In some cases, however, it is difficult to obtain adequate biopsy samples for pathological diagnosis.
Adequate prediction of the diagnostic accuracy of TBB with EBUS-GS is important before deciding whether
bronchoscopy should be performed.
Methods: We retrospectively reviewed 149 consecutive patients who underwent TBB with EBUS-GS for small-sized
peripheral lung lesions (≤30 mm in diameter) from April 2012 to March 2013. We conducted an exploratory
analysis to identify clinical factors that can predict an accurate diagnosis by TBB with EBUS-GS. All patients
underwent thin-section chest computed tomography (CT) scans (0.5-mm slices), and the CT bronchus sign was
evaluated before bronchoscopy in a group discussion. The final diagnoses were pathologically or clinically
confirmed in all studied patients (malignant lesions, 110 patients; benign lesions, 39 patients).
Results: The total diagnostic yield in this study was 72.5 % (95 % confidence interval: 64.8–79.0 %). Lesion size,
lesion visibility on chest X-ray, and classification of the CT bronchus sign were factors significantly associated with
the definitive biopsy result in the univariate analysis. In the multivariate analysis, only the CT bronchus sign
remained as a significant predictive factor for successful bronchoscopic diagnosis. The CT bronchus sign was also
significantly associated with the EBUS findings of the lesions.
Conclusion: Our results suggest that the CT bronchus sign is a powerful predictive factor for successful TBB with
EBUS-GS.
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Recent studies of lung cancer screening by low-dose
computed tomography (CT) have demonstrated a defin-
ite advantage for detecting early-stage lung cancer [1–3].
Both chronic obstructive pulmonary disease and pul-
monary fibrosis, rapidly growing health problems espe-
cially in the older population, are frequently associated
with lung cancer [4, 5]. In patients with such diseases, a
chest CT scan is essential for disease evaluation or mon-
itoring. An increasing number of small-sized peripheral
lung lesions are being found incidentally during the
follow-up of these diseases [6]. Accordingly, there is an
urgent need for the development of strategies to confirm
the pathological diagnosis of small-sized lung lesions.
Bronchoscopy has been the mainstay diagnostic method
for pulmonary lesions. Recent advances in newer bron-
choscopic techniques, such as endobronchial ultrasound
(EBUS) or the use of virtual navigation systems, have en-
abled us to approach small peripheral lung lesions that
are invisible on fluoroscopy [7]. However, recent studies
have shown that a final diagnosis cannot be reached by
bronchoscopy even with the most advanced techniques
available today in a certain percentage of patients [8].
Recent developments in molecular targeted therapy
for lung cancer have increased the need to obtain bron-
choscopic biopsy specimens sufficient for molecular
analysis [9]. Various diagnostic procedures other than
bronchoscopy, such as CT-guided percutaneous needle
aspiration biopsy (CTNAB) and surgical biopsy, are also
available. Physicians must choose the most suitable
procedure with which to establish a diagnosis in pa-
tients who present with lung lesions. It is very import-
ant to predict the possibility of obtaining an adequate
bronchoscopic tissue specimen for pathological and
molecular diagnosis. Based on the present analysis, CT
bronchus sign on thin-section CT (TSCT) at the initial
evaluation seems to be the most reliable predictive fac-
tor for successful biopsy by bronchoscopy. The results
of this study provide both patients and doctors with
useful information that will allow for informed consent
in the selection of a diagnostic procedure.Methods
Patients
The medical records of consecutive patients who under-
went bronchoscopy in Fujita Health University Hospital
from April 2012 to March 2013 were retrospectively
reviewed. The institutional review committee (Fujita
Health University Institutional Review Board) approved
this study protocol, which was conducted in accordance
with the tenets of the Declaration of Helsinki (approval
number Fujita 14-152). All patients provided written in-
formed consent before undergoing bronchoscopy.Evaluation before bronchoscopy
All patients underwent chest TSCT (0.5 mm slice)
within 1 month before bronchoscopy. TSCT images
were generated using a nonenhanced multidetector CT
system (Aquilion One Vision Edition; Toshiba Medical
Systems, Tokyo, Japan). The CT scan parameters were as
follows: tube current, automatic exposure control SD7;
tube voltage, 120 kV; rotation speed, 0.5 s/rot; table
speed, BP 1.39; reconstruction filter, FC51 AIDR 3D
WEAK; window width, 1600; and window level, −600.
We used automatic exposure control, the volume helical
scan mode, and multi-planar reconstruction images.
We did not use a virtual bronchoscopic navigation
system. Each bronchoscopist studied the patient’s chest
X-ray and TSCT images before the procedures and iden-
tified the size and location of the lesions and the respect-
ive bronchus. In every case, we confirmed these findings
and identified the target bronchus to approach by group
discussion. We investigated the bronchus sign on CT,
which was identified as the presence of a bronchus dir-
ectly leading to the target lesion (CT bronchus sign)
[10]. In each case, we categorized the relationship be-
tween the target lesion and the nearest bronchus into
three types of CT bronchus signs (A to C). In type A,
the responsible bronchus clearly reached the inside of
the target lesion. In type C, no bronchus could be de-
tected in relation to the lesion. When the CT findings
could be categorized into neither type A nor C, the CT
bronchus sign was categorized as type B (Fig. 1). Two
bronchoscopists (T.M. and K.I.) independently assessed
each TSCT scan and determined the type of each CT
bronchus sign (A, B, or C). When the two bronchoscopists
recommended different types, the final type was deter-
mined by discussion.
Bronchoscopic procedures
After administration of local pharyngeal anesthesia, all
patients were lightly sedated with individually calculated
dose of intravenous midazolam as reported elsewhere
[11]. Transbronchial biopsy (TBB) using EBUS with a
guide sheath (EBUS-GS) was performed according to
the standard Kurimoto method [12]. A 20-MHz radial
type ultrasound probe with an external diameter of
1.4 mm (UM-S20-17S; Olympus Medical Systems,
Tokyo, Japan) connected to an endoscopic ultrasonog-
raphy system (EU-M30S; Olympus Medical Systems)
was used in all cases. We mainly used a bronchoscope
with a 2.0-mm-diameter working channel (BF-P260F;
Olympus Medical Systems) for a guide sheath with an
external diameter of 1.9 mm (K-201 kit equipped with a
biopsy forceps and cytological brush; Olympus Medical
Systems). According to the size or location of the lesion,
the operator could use a 1T260 bronchoscope with a
2.6-mm-diameter working channel with the guide sheath
CT bronchus sign A CT bronchus sign B CT bronchus sign C
Fig. 1 CT bronchus sign. According to TSCT (0.5-mm reconstruction), we categorized the CT bronchus sign in each case into three types a to c
according to the relationship between the nearest bronchus and the target lesion. In type A, the responsible bronchus clearly reached the inside
of the target lesion. In type C, no bronchus could be detected in relation to the lesion. When the CT findings could be categorized into neither
type A nor C, the CT bronchus sign was categorized as type B
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(Olympus Medical Systems). We took 12 biopsy samples
when using the K201 kit and nine samples using the K203
kit. Nine bronchoscopists performed the procedures in
this study. Five of them had less than 7 years of experience
as a bronchoscopist (range: 2–6 years), whereas four had
more experience (range: 7–21 years).
Diagnostic evaluation of TBB results (positive diagnostic
criteria by bronchoscopy)
In this study, we evaluated the bronchoscopic diagnostic
yield in both malignant and non-malignant diseases (in-
cluding inflammatory disease). Thus, we determined the
evaluation criteria for judgment of successful (diagnos-
tic) bronchoscopy according to previous reports [8, 13].
Lesions with evident malignant findings on histological
examination or class IV/V findings on cytological exam-
ination were defined as malignant. For benign lesions,
when bronchoscopy demonstrated a distinct histologic
pattern (such as epithelioid granuloma or intra-alveolar
organization) or the presence of bacteria accompanied
by reasonable radiologic and clinical findings, we deter-
mined that the bronchoscopy was successful. All benign
lesions were followed for more than 12 months to con-
firm that the lesions had remained stable or improved
by appropriate therapy.
Statistical methods
Statistical analyses were carried out using JMP software
(ver. 8.0; SAS Institute, Inc., Cary, NC). A binomial pro-
portion confidence interval (CI) was calculated fordiagnostic yield. Differences in proportions were evalu-
ated with the χ2 test. Spearman rank correlation was
used to identify the association between two ordinal var-
iables. Multivariate logistic regression analysis was used
to identify factors associated with diagnostic yield inde-
pendent of other variables. We entered all variables that
were significantly (p < 0.05) associated with diagnostic
yield in the univariate analyses into the multivariate ana-
lysis. The final model was determined by a backward
variable selection method, and odds ratios and the 95 %
CIs are presented. A p-value of <0.05 was considered to
indicate statistical significance. All analyses were two-
sided.
Results
Patient characteristics and details of lesions
We retrospectively reviewed 149 consecutive patients
who underwent TBB with EBUS-GS. Table 1 shows the
characteristics of the studied patients and targeted le-
sions. The median age of the patients was 70 years
(range: 32–86 years). There was no sex difference. The
size of the lesions ranged from 7.5 to 29.7 mm, and the
median size was 19.6 mm. Five patients (3.4 %) had le-
sions smaller than 10 mm in diameter. Seventy-seven le-
sions (51.7 %) were located in the upper lobe and 17
(11.3 %) were located in superior segment of the lower
lobe. Twenty-one cases (14.1 %) exhibited ground glass
opacity (GGO), including 17 cases with pure GGO le-
sions. The number of bronchial branches that reached
the target lesion from the trachea ranged from 3–8
(median: 5). Chest X-ray and TSCT were assessed as




yrs. median (range) 70 (32–86)
Gender
Male, number (%) 86 (57.7 %)
Female, number (%) 63 (42.3 %)
Variable (lesions)
Size of the lesion (diameter)
mm, median (range) 19.6 (7.5–29.7)
Location of the lesions
Upper lobe 77 (51.7 %)
Lingular lobe or middle lobe 19 (12.8 %)
Superior segment of the lower lobe 17 (11.3 %)
Lower lobe (except for superior segment) 36 (24.2 %)
Chest X-ray findings of the lesions
Clearly visible 77 (51.7 %)
Vague or invisible 72 (48.3 %)
Thin slice CT features
GGO 21 (14.1 %)
Solid 128 (85.9 %)
Number of the branch reach to the lesion
mean 5.03
3 12 (7.9 %)
4 32 (21.5 %)
5 55 (36.9 %)
6 35 (23.6 %)
7 12 (8.1 %)
8 3 (2.0 %)
CT bronchus sign a
A 86 (57.8 %)
B 49 (32.9 %)
C 14 (9.3 %)
GGO ground glass opacity, aCT bronchus sign: see Methods
Table 2 Final diagnosis of targeted lesions (n = 149)
Malignancy (n = 110)
Lung cancer
Adenocarcinoma 72
Squamous cell carcinoma 14
Large cell carcinoma 2
NSCLC 4
Adenosquamous 1
Small cell carcinoma 4
Metastatic cancer 12
Lymphoma 1










NSCLC non-small cell lung cancer, not otherwise specified, NTM
non-tuberculosis mycobacteriosis. Others include pulmonary infarction
and asbestos-related fibrosis
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garding whether to perform bronchoscopy. On the ini-
tial chest X-rays, the targeted lesions were clearly
visible in 77 patients (51.7 %) and vague or invisible in
72 patients (48.3 %). After careful assessment of chest
TSCT by two bronchoscopists, we determined the type
of CT bronchus sign of each lesion: A (86 lesions,
57.8 %), B (49 lesions, 32.9 %), and C (14 lesions, 9.3 %)
(Table 1, Fig. 1). The median bronchoscopic examin-
ation time was 55 min (range: 43–71 min). The mean
total dose of lidocaine used was 345 mg (range: 240–
550 mg). Ten patients (6.7 %) had complications
including five with pneumothorax requiring pleuraldrainage, four with pneumonia and one with a transient de-
lirium. No severe complications occurred during this study.
Final diagnosis of targeted lesions are shown in Table 2.
Factors associated with bronchoscopic diagnosis
In total, 72.5 % (95 % CI: 64.8–79.0) cases could be diag-
nosed with TBB using EBUS-GS. The diagnostic yield of
malignant diseases and non-malignant diseases was
78.2 % and 56.4 %, respectively (Table 3). The diagnostic
yield was significantly higher in malignant than in non-
malignant diseases (p = 0.0089). We examined clinical
factors that can be obtained at the outpatient clinic for
their potential ability to predict the bronchoscopic diag-
nostic yield. Lesion diameter, lesion visibility on chest X-
ray, and the CT bronchus sign were significantly associ-
ated with the diagnostic yield in the univariate analyses
(Table 4). In the logistic regression analysis, the CT
bronchus sign was the only significant factor associated
with successful achievement of a bronchoscopic diagno-
sis. The diagnostic success rate for lesions with a CT
bronchus sign type A was 11.1 times higher than that
for lesions with a CT bronchus sign type C (Table 5).
More than 90 % of malignant lesions with a CT bron-
chus sign type A could be diagnosed successfully. Con-
versely, the bronchoscopic diagnostic yield was
extremely low in lesion with a CT bronchus sign type C
Table 3 Diagnostic yield (all cases)
Diagnostic yield
All cases 72.5 % (108/149)
Malignancy 78.2 % (86/110)
Non-malignancy 56.4 % (22/39) p = 0.0089*
*Significant difference between malignancy and benign lesions
Table 5 Logistic regression analysis of factors on diagnostic
yield of TBB using EBUS-GS
Variables HR (95%CI) p value
Visibility on Chest X-ray Clearly visible 2.03 0.90–4.59 P = 0.087
Vague or invisible Ref.
CT bronchus signa A 11.1 2.99–41.2 P < 0.001*
B 4.62 1.24–17.2 P = 0.023*
C Ref.
* significant difference, a See Methods. Ref. reference
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lesions, respectively) (Fig. 2).
Diagnostic yield according to the combination of CT
bronchus sign with chest X-ray findings and lesion size
In the daily clinical setting, we must decide whether a
patient should undergo bronchoscopy at the initial
evaluation in the outpatient clinic. Informed consent for
bronchoscopy should include the probability of establishing
a pathological diagnosis. We evaluated the diagnostic yield
of bronchoscopy according to the combination of a CT
bronchus sign, lesion visibility on the initial chest X-ray,
and lesion size (Table 6). When target lesions with a CT
bronchus sign type A were clearly visible on chest X-ray,
the diagnostic yield for the lesions was high (88.0 % for all
lesions and 98.6 % for malignant lesions). The diagnostic
yield for malignant lesions with both a CT bronchus sign
type A and clear visibility on chest X ray was extremely
high (100.0 % for lesions 20–30 mm in diameter and
94.6 % for those <20 mm diameter). When the target le-
sions showed a CT bronchus sign type B accompanied by
vague or invisible chest X-ray findings, the diagnostic yield
was around 60 %. In five patients with lesions of <10 mm
in diameter (range: 7.5–9.9 mm) (type A in two patientsTable 4 Contribution of clinical factors available before bronchosco
Variables
Lesion diameter <20 mm
≥20 mm
Lesion location Upper lobe or su
Middle or lower
Feature of the lesion GGO
Solid
Visibility of the lesion on Chest X-ray Clearly visible
Vague or invisibl
Number of bronchial branch to reach the lesion ≥5
≤4
Operator’s experience (years) ≥7
≤6
CT bronchus signb A
B
C
* significant difference, a except for superior segment of the lower lobe, b See Methand B in three patients), a bronchoscopic diagnosis could
be obtained in both patients with the type A sign. In 17
patients with pure GGO lesions, the CT bronchus signs
were A in 10 lesions, B in 5 lesions and C in two lesions.
The diagnostic yield was 80 % in type A, 60 % in B, and
0 % in C.
Relationship between CT bronchus sign and EBUS
findings
Previous reports have emphasized the role of the EBUS
findings of the target lesion for successful bronchoscopic
diagnosis [12, 14]. When an EBUS probe is located in
the center of (“within”) the target lesion, the probability
of successful diagnosis would be higher than when the
probe is located next to (“adjacent to”) or outside (“in-
visible”) the target lesion. Thus, we evaluated the rela-
tionship between the CT bronchus sign and EBUS
findings in each case. As shown in Fig. 3, the CT bron-
chus sign and EBUS findings were well correlated with
each other (Spearman rank correlation coefficient r =
0.556, p < 0.001). Nearly 70 % of lesions with a CTpy to diagnostic yield (all cases)
Diagnostic yield p value
51/80 (63.8 %) 0.01*
57/69 (82.6 %)
p segment of lower lobe 40/56 (71.4 %) 0.82
lobe a 68/93 (73.1 %)
12/18 (66.7 %) 0.24
96/131 (73.2 %)
59/72 (81.9 %) 0.01*
e 49/77 (63.6 %)
35/50 (70.0 %) 0.63
73/99 (73.7 %)
34/52 (65.4 %) 0.16
74/97 (76.3 %)




Fig. 2 CT bronchus sign and bronchoscopic diagnostic yield. The CT bronchus sign was a significant factor associated with a positive bronchoscopic
diagnosis. In particular more than 90 % of malignant lesions with a CT bronchus sign type A could be diagnosed successfully. Conversely, in benign
lesions, the bronchoscopic diagnostic yield was 0 % in lesions with a CT bronchus sign type C
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EBUS.
Discussion
It is clinically important to determine which diagnostic
modality would be the most reliable and safest for pa-
tients with unknown peripheral lesions in the outpatient
clinic. Although recent advances in bronchoscopic tech-
nologies, including EBUS-GS, have improved the diag-
nostic yield of bronchoscopy, other modalities such as
CTNAB or surgical biopsy might be preferable for some
patients. However, these procedures may also be associ-
ated with specific complications. Notably, CTNAB is
often complicated by pneumothorax and occasionally
more serious complications such as air embolism orTable 6 Diagnostic yield according to the CT bronchus sign, Chest




Vague or invisibletumor dissemination along the biopsy route [15]. Thus,
it is sometimes difficult to recommend the most suitable
diagnostic method to a patient at the initial evaluation.
Our study shows that the CT bronchus sign as evaluated
by TSCT is the most powerful predictive factor for suc-
cessful bronchoscopic diagnosis of small peripheral le-
sions. The physician should encourage the patient to
undergo bronchoscopy if the target lesion exhibits a CT
bronchus sign type A. On the contrary, if the patient’s
lung lesion shows a CT bronchus sign type C, the patient
should be offered an alternative diagnostic procedure,
such as CTNAB or surgical biopsy.
In this study, we assessed all patients’ TSCT images as
their radiological findings at their initial evaluation.
However, because it may be difficult to perform TSCTX-ray findings and lesion size













Fig. 3 Relationship between CT bronchus sign and EBUS findings. The CT bronchus sign was highly correlated with the EBUS findings Spearman
rank correlation coefficient r = 0.556, p < 0.001. Nearly 70 % of lesions with a CT bronchus sign type A showed a “within” finding on EBUS
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only be valid for bronchoscopy performed at medical
centers or educational hospitals in which TSCT is readily
available. Future studies are warranted to assess whether
conventional CT findings can also be used to predict the
results of bronchoscopic biopsy. Our retrospective ana-
lysis may also indicate that the differential broncho-
scopic diagnostic yield can be determined according to
the combination of the CT bronchus sign and chest X-
ray findings. This would be useful information that
could be offered to patients as a standard method by
which to estimate the diagnostic yield of TBB with
EBUS-GS. However, these issues must be confirmed in a
future prospective study.
Other reports have emphasized that EBUS findings are
the most important factor for obtaining pathological re-
sults in bronchoscopy with EGUS-GS [12, 14]. These re-
ports have shown that an EBUS finding of “within,”
which means that an EBUS probe can be introduced in-
side the lesion, is strongly related to a high diagnostic
yield. In the present study, we demonstrated that a CT
bronchus sign type A was significantly related to a
“within” EBUS finding. These results might indicate that
we can predict EBUS findings from the CT bronchus
sign on TSCT at the initial evaluation. Most recently,
Evison et al. [16] reported that the presence of a bron-
chus sign on CT was the only independent predictor of
all predefined outcomes, including lesion identification
with radial EBUS, positioning of the probe within the
center of the lesion, and accurate pathological diagnosis.
However, they evaluated larger lesions (nearly 70 % of le-
sions were >30 mm in diameter) than those in the present
study (all lesions were <30 mm in diameter). Our study
cohort included five patients with lesions of <10 mm in
diameter and 17 with pure GGO lesions. Although thediagnostic yields in these cases were lower than in other
cases, a CT bronchus sign type A was still well correlated
with a higher diagnostic yield. Taken together, our results
clearly indicate that a CT bronchus sign is a powerful pre-
dictor of successful bronchoscopy, even in smaller lung
lesions.
Our study has some limitations. First, this was a retro-
spective analysis in a single institution. Because the diag-
nostic yield may vary among institutions, the usefulness
of the CT bronchus sign should be confirmed in a multi-
center prospective study. Notably, in the present study,
young bronchoscopists with less than 7 years of experi-
ence performed about two-thirds of all procedures, and
the experience level of the examiner was not related to
the diagnostic yield. We speculated that the usefulness
of the CT bronchus sign may be universal and inde-
pendent of differences among institutions or bronchos-
copists. Second, it has been reported that the ability to
obtain a fluoroscopic view of the lesion significantly in-
fluences the success of a bronchoscopic diagnosis. How-
ever, a fluoroscopic view of the target lesion is usually
difficult to obtain at the patient’s first visit to an out-
patient clinic. Therefore, we assessed the chest X-ray
findings of the target lesions at the initial evaluation in
this study. Third, we did not use a virtual navigation system
or rapid on-site examination of the cytological findings.
Both of these methods are well known to improve the
bronchoscopic diagnostic yield even when using the
EBUS-GS system [17–19]. However, we also showed a
higher diagnostic yield than those reported in previous
studies that used a virtual navigation system and/or rapid
on-site examination. Based on the findings of this study,
we can say that the CT bronchus sign is an important and
useful predictive marker with or without the use of virtual
technology or on-site cytological evaluation.
Minezawa et al. BMC Medical Imaging  (2015) 15:21 Page 8 of 8Conclusions
In summary, the CT bronchus sign associated with target
lesions on TSCT is a useful predictive marker for successful
bronchoscopic diagnosis of small peripheral lung lesions.
Physicians should perform TSCT and evaluate the CT
bronchus sign associated with the target lesion before
deciding whether bronchoscopy is suitable for the patient.
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